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Abstract
Parkinson's disease (PD) is the most common neurodegenerative movement disorder. Although a
subject of intense research, the etiology of PD remains poorly understood. Recently, several lines
of evidence have implicated an intimate link between aberrations in the ubiquitin proteasome
system (UPS) and PD pathogenesis. Derangements of the UPS, which normally functions as a type
of protein degradation machinery, lead to alterations in protein homeostasis that could conceivably
promote the toxic accumulation of proteins detrimental to neuronal survival. Not surprisingly,
various cellular and animal models of PD that are based on direct disruption of UPS function
reproduce the most prominent features of PD. Although persuasive, new developments in the past
few years have in fact raised serious questions about the link between the UPS and PD. Here I
review current thoughts and controversies about their relationship and discuss whether strategies
aimed at mitigating UPS dysfunction could represent rational ways to intervene in the disease.
Publication history: Republished from Current BioData's Targeted Proteins database (TPdb;
http://www.targetedproteinsdb.com).
Parkinson's disease
Parkinson's disease (PD) is the most common neurode-
generative movement disorder, affecting millions of eld-
erly individuals worldwide [1,2]. Clinically, the disease is
characterized by major motoric difficulties that include
bradykinesia, postural instability, rigidity and tremor.
Although neurodegeneration in PD involves multiple
areas of the brain such as the dorsal motor nucleus of the
vagus, locus ceruleus (LC) and olfactory nuclei [3], the
principal neuropathology that gives rise to the array of
motoric deficits seen in PD patients is the loss of
dopaminergic neurons in the substantia nigra pars com-
pacta (SNpc), which results in a severe depletion of striatal
dopamine (DA) [4]. Often, the neuronal degeneration is
accompanied by eosinophilic intracytoplasmic inclusions
known as Lewy bodies (LBs) that are present in surviving
neurons of the SN as well as in other affected brain areas
[5]. However, the LB is not an obligate marker of the dis-
ease as some familial PD cases are apparently devoid of its
presence [6-9].
Although a subject of intense research, the etiology of PD
remains poorly understood and no treatment exists to
prevent, cure or retard the progression of this disabling
disease. Current favored hypotheses for sporadic PD
include combinations of the aging process, genetic pro-
pensity and environmental exposures leading to oxidative
stress, mitochondrial dysfunction, microglial activation
and excitotoxicity [2,10]. More recently, evidence from
several lines of study strongly implicate a key role for the
ubiquitin proteasome system (UPS) in PD pathogenesis
[11-14].
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UPS
The UPS is an intracellular protein degradation system
that is responsible for the majority of protein turnover
within the cell [15] (Figure 1). In this system, proteins des-
tined for degradation are covalently tagged with ubiqui-
tin, a 76 amino acid residue protein, through the
formation of an iso-peptide bond between the ε-amino
group of a lysine residue of the substrate and the C-termi-
nal carboxylate (G76) of ubiquitin. This ligation reaction
is elaborate and requires the sequential actions of ubiqui-
tin activating (E1), conjugating (E2) and ligating (E3)
enzymes [16] (Figure 1). Usually, the multienzyme-medi-
ated ubiquitylation process is repeated many times to
allow the formation of a polyubiquitin chain on the sub-
strate. Ubiquitin molecules in the chain are linked
together via iso-peptidic bonds between the terminal G76
residue of each ubiquitin unit and a specific lysine (K) res-
idue (most commonly K48) of the previous ubiquitin
[17]. The G76–K48 polyubiquitylated substrate is then
targeted for degradation by the 26S proteasome, a large
protease complex consisting of a barrel-shaped 20S prote-
olytic core in association with two 19S (PA700) regulatory
caps, one on each side of the barrel's openings (Figure 1).
The 20S catalytic core is characterized by three distinct
proteolytic activities: chymotrypsin-like, trypsin-like and
peptidyl glutamylpeptide hydrolytic, which can be meas-
ured in vitro by means of a fluorimeter using Suc-Leu-Leu-
Val-Try-AMC, Boc-Leu-Arg-Arg-AMC and Z-Leu-Leu-Glu-
AMC, respectively, as fluorogenic peptide substrates [18].
The components of the 19S cap play vital roles in the ini-
tial steps of substrate proteolysis, including the recogni-
tion, unfolding and translocation of substrate proteins
into the lumen of the proteolytic core [19-21]. Individual
ubiquitin monomers are regenerated in the process by the
actions of deubiquitylating enzymes (DUBs) (Figure 1). It
is important to note that the ubiquitin molecule contains
a total of seven lysine residues (at positions 6, 11, 27, 29,
33, 48 and 63) and that polyubiquitin chain assembly via
alternative lysine linkages has also been described [22].
Notably, K63-linked polyubiquitylation of proteins is not
typically associated with proteasomal degradation [23-
27]. It is also noteworthy that an enormous number of
cellular proteins (>1000), comprising various E1s, E2s,
E3s and other related members, are involved in the UPS
[28]. Indeed, protein ubiquitylation rivals protein phos-
phorylation as a major post-translational event in the cell.
Conceivably, therefore, derangements of UPS function
could lead to dire cellular consequences, particularly in
post-mitotic cells.
UPS and PD
Evidence implicating a direct role for the UPS in PD came
from the association of genetic mutations in the parkin
(PRKN2) gene with familial parkinsonism about a decade
ago [13], and the subsequent demonstration by three
independent groups that parkin functions as a ubiquitin
ligase associated with proteasomal degradation [29-31].
Importantly, using in vitro assays to measure the ubiquit-
ylation activity of parkin immunoprecipitated from trans-
fected cells, these pioneer investigators found that disease-
causing mutations in parkin compromise its normal role
as an E3 enzyme [29-31]. This property of parkin thus
directly links UPS aberrations to dopaminergic neuronal
survival, the association of which is further supported by
the discovery of a missense mutation (I93M) in UCHL1, a
DUB, in a pair of German siblings with inherited PD [14].
Notably, the I93M UCHL1 mutant has markedly reduced
ubiquitin hydrolase activity in vitro[14], suggesting that
impaired polyubiquitin hydrolysis could also contribute
to dopaminergic neuronal death. Another PD-linked gene
product, α-synuclein, is a major component of LBs [32].
Although α-synuclein is not a member of the UPS, overex-
pression of wild-type or mutant α-synuclein in cultured
cells and in the brains of transgenic mice is known to
inhibit proteasome function (as determined by in vitro
20S proteasome assay), with disease-relevant mutants
eliciting stronger effects [33-35]. Notably, triplication of
the α-synuclein gene is also causative of PD [36].
Consistent with an implicated role for the UPS in familial
parkinsonism, McNaught and colleagues (Mount Sinai
School of Medicine) observed a significant reduction in
the levels of PA700 expression in the SNpc of post-mor-
tem sporadic PD brains relative to control brains [11]
(PA700 levels are otherwise elevated in other regions of
the PD brain such as the frontal cortex and striatum
[11,37]). Selective decrease in the level of proteasomal
core subunits within the SN was also noted [11]. Further,
in vitro assay of SN extracts from PD brains revealed a
marked decrease in the activity of the 20S proteasome
[11]. Corroborating evidence came from a parallel report
by Spillantini and co-workers (Cambridge Centre for
Brain Repair) who demonstrated a 55% reduction in the
proteasomal chymotrypsin-like activity in the SN, but not
in the cingulate, frontal and occipital cortices, of PD
brains [38]. Together, these results suggest structural and
functional impairments of the UPS in sporadic PD.
Although the precise basis of UPS dysfunction in sporadic
PD awaits further clarifications, it likely involves age-
related changes in the brain resulting in increased oxida-
tive stress and energy depletion, as well as exposures to
environmental toxins [39,40]. Supporting this, the herbi-
cide maneb and a range of pesticides linked to sporadic
PD, including rotenone, have been shown to produce pro-
teasome inhibition in vitro[41,42]. Similarly, we recorded
a marked decrease in proteasome activity in extracts
derived from rotenone- and paraquat-treated cells relative
to untreated controls [43]. Further, Betarbet et al. (Emory
University) found that proteasome function is selectively
decreased in the ventral midbrain region in rotenone-BMC Biochemistry 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2091/8/S1/S13
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The ubiquitin proteasome system (UPS) and Parkinson's disease (PD) Figure 1
The ubiquitin proteasome system (UPS) and Parkinson's disease (PD). Under normal conditions, proteins destined 
for proteasomal degradation are tagged with a chain of ubiquitin (Ub) proteins via multiple rounds of a linear reaction catalyzed 
by ubiquitin activating (E1), conjugating (E2) and ligating enzymes (E3). An example of an E3 is parkin. Ubiquitylation reactions 
are reversed by the action of deubiquitylating enzymes (DUBs), of which UCHL1 is a member. Energy in the form of ATP is 
required to drive the UPS machinery. Age-related changes, exogenous stress, mitochondrial alterations and PD-linked genetic 
mutations in parkin, UCHL1 and α-synuclein could promote disruption of the UPS and conceivably result in the accumulation 
of protein aggregates or abnormal protein intermediates that could be directly detrimental to neuronal survival. Lewy bodies 
are thought to form as a result of an attempt by the cell to sequester these abnormal proteins. The enhancement of protein re-
folding by chaperones such as Hsp70 and the clearance of protein aggregates via the stimulation of autophagy could help miti-
gate UPS dysfunction. Such strategies may offer innovative approaches in the treatment of PD.BMC Biochemistry 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2091/8/S1/S13
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induced rats [42], while a similar study by another group
(University of Pisa) showed that continuous infusion of
the parkinsonian neurotoxin, MPTP, in mice induces pro-
teasome impairments in their brains [44]. Taken together,
these results suggest a co-operative relationship between
environmental exposures and proteasome dysfunction in
promoting neurodegeneration in sporadic PD.
How does failure of the UPS lead to dopaminergic neuro-
degeneration? Conceivably, aberrant protein homeostasis
could result in the toxic accumulation of intracellular pro-
teins detrimental to neuronal survival. Supporting this,
the accumulation of misfolded and aggregated α-synu-
clein is thought to be the primary pathogenic event in
familial PD linked to mutations or multiplication of the
α-synuclein gene [45]. Notably, aggregated α-synuclein
selectively interacts with the 19S cap and concomitantly
inhibits the function of the 26S proteasome [46], thereby
perpetuating a vicious cycle. Similarly, in parkin-linked
parkinsonism, the accumulation of certain parkin sub-
strates could interfere with cellular functions and induce
neurotoxicity [45]. Indeed, numerous reported substrates
of parkin, including CDCrel (cell division control-related
protein) 1 and 2a [47], Pael-R (parkin-associated
endothelin-like receptor) [48], cyclin E [49], p38 (JTV-1/
AIMP2) [50] and FBP1 (far upstream sequence element-
binding protein 1) [51], accumulate in the brains of PD
patients carrying parkin mutations. Further, both p38 and
FBP1 also accumulate in the brains of parkin-deficient
mice [50,51], and overexpression of p38 in cell culture or
SN of mice leads to marked neurotoxicity [50]. Taken
together, these results suggest that parkin-mediated ubiq-
uitylation of its substrates promotes their turnover via the
UPS and offer a simple hypothesis that toxic substrate
accumulation in the absence of functional parkin triggers
neurodegeneration. However, because none of these par-
kin substrates are exclusively expressed in dopaminergic
neurons, it remains puzzling as to why dopaminergic neu-
rons are selectively vulnerable to parkin deficiency. None-
theless, the importance of parkin function to neuronal
survival is currently widely accepted. This is exemplified
by its broad neuroprotective capacity, which includes con-
ferring protection against manganese-induced cell death
[52], α-synuclein toxicity [53], Pael-R [54] and p38/JTv-1
accumulation [50], kainate-induced excitotoxicity [49],
DA-mediated toxicity [55], and importantly, proteasome
dysfunction [43,56]. Accordingly, the loss of parkin func-
tion following its mutation is expected to compromise
neuronal survival. Interestingly, a recent ubiquitylation
assay conducted by Tanaka (Tokyo Metropolitan Institute
of Medical Science) and Corti (INSERM) laboratories
using purified recombinant parkin demonstrated that the
majority of disease-associated parkin missense mutations
do not compromise its enzymatic activity in vitro[57,58].
Conversely, several other groups, including ours, found
that parkin mutations often alter the protein's solubility
and concomitantly promote its aggregation within the cell
[59-62]. Further, we and others also found that normal
brain aging, as well as a wide variety of PD-linked stres-
sors, including DA, induce similar alterations in parkin
[43,63,64] or otherwise inactivate the enzyme [65,66],
thereby suggesting a mechanism for parkin dysfunction in
the pathogenesis of idiopathic PD. Loss of soluble, func-
tional parkin resulting from normal aging or stress-
induced modifications could therefore be as relevant to
sporadic PD as parkin dysfunction triggered by disease-
associated mutations is to parkin-related parkinsonism.
Disease models, knockouts and assays
Using fetal rat ventral mesencephalic cultures as a model,
several groups have demonstrated that lactacystin-
induced proteasome dysfunction results in a dose-
dependent and preferential degeneration of dopaminergic
neurons, accompanied by the formation of inclusion bod-
ies that stain positively for ubiquitin and α-synuclein
[67,68]. Interestingly, inactivation of ubiquitin hydro-
lases with ubiquitin aldehyde produces similar effects in
these primary cultures [67]. However, these studies were
performed using acute doses (5–10 µM for 24–48 hours)
of pharmacological inhibitors. To better reflect the events
occurring in susceptible neurons during PD pathogenesis,
Keller and co-workers (University of Kentucky) subjected
SH-SY5Y neuroblastoma cells to low levels of proteasome
inhibition (100 nM MG115) for an extended period last-
ing several weeks. They observed in these cells elevated
levels of protein oxidation and protein aggregates, as well
as altered mitochondrial homeostasis [69,70]. Neural
cells exposed to chronic proteasome inhibition thus
reproduce the key features of sporadic PD faithfully
[69,70], thereby supporting the involvement of UPS aber-
rations in PD pathogenesis. Consistent with this, two
groups observed retrograde dopaminergic neurodegener-
ation in rodent brains following intrastriatal administra-
tion of lactacystin [71,72]. In further pursuit of this
hypothesis, McNaught and colleagues subjected adult
Sprague-Dawley rats to six regularly-spaced subcutaneous
injections of either the naturally occurring proteasome
inhibitor epoxomicin (1.5 mg/kg) or the synthetic protea-
some inhibitor PSI (3 or 6 mg/kg) over a period of two
weeks [73]. Remarkably, after a latency of two weeks, both
inhibitors induced progressive motor dysfunction charac-
terized by bradykinesia, rigidity and tremor in treated rats
that could be alleviated by L-DOPA administration [73].
Consistent with the loss of dopaminergic nerve terminals
in the striatum, 11C-CFT-based positron emission tomog-
raphy imaging revealed a progressive reduction of the DA
transporter ligand in these rats [73]. The nigral pathology,
as well as extra-nigral degeneration in brain regions such
as the LC, dorsal motor nucleus of the vagus and nucleus
basalis of Meynert, was confirmed at post mortem [73].BMC Biochemistry 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2091/8/S1/S13
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Whereas a reduction in proteasome activity, as measured
in vitro, appears to accompany the degeneration, elevated
proteasome activity was observed in areas that remained
intact, suggesting a compensatory mechanism [73]. Nota-
bly, inclusions that stained positively for ubiquitin and α-
synuclein formed within neurons that survived the degen-
eration process in affected areas [73]. This rat model of
PD, based on systemic administration of proteasome
inhibitors, thus recapitulates the key clinical and patho-
logical hallmarks of PD faithfully and provides solid sup-
port for the role of UPS disruption in PD pathogenesis.
Unfortunately, the model is currently controversial as sev-
eral laboratories have recently reported failures in their
attempts to replicate the results despite diligently adher-
ing to McNaught's original protocol [74-76]. These con-
flicting findings include the absence of nigral pathology,
motor impairment and neuronal inclusions [74-76].
However, some other groups did manage to reproduce the
nigral pathology [77,78]. Though the reason for this vari-
ability is currently unclear, it could be due to variations in
the source and hence quality of the inhibitors, differences
in methodologies or exogenous factors present in feeds or
in the environment [79,80]. Hopefully, these issues will
soon be resolved as the novel model of PD generated by
McNaught and colleagues is arguably one that reflects the
disease most accurately and as such has important impli-
cations for the development of PD therapeutics.
Concurrent to the proteasome inhibition model, several
investigators have also generated genetic models of PD to
probe the link between the disruption of key UPS players
and PD pathogenesis. Two groups, led by Shen (Harvard
Medical School) and Rooney (Aventis Pharma) respec-
tively, first reported mouse models that are ablated of
orthologous parkin[81,82]. However, none of these mod-
els exhibit parkinsonian phenotypes. Indeed, with the
exception of cell loss in the LC in a subsequent model gen-
erated by the Dawson laboratory (Johns Hopkins School
of Medicine) [83], parkin null mice have generally failed
to exhibit apparent signs of parkinsonism [81,82,84]. Fur-
ther, the majority of previously identified parkin sub-
strates (except p38 and FBP) do not show any detectable
accumulation in these mice [50,51,81,82,84]. Similarly,
inactivation of UCHL1 in mice leads not to dopaminergic
neuronal death but to gracile axonal dystrophy syndrome,
a degenerative disease associated with sensory and motor
ataxia [85]. However, Drosophila parkin null mutants,
originally developed by Greene et al. (University of Wash-
ington) [86], exhibit selective dopaminergic neurodegen-
eration in the adult brains and concomitant locomotion
defects [87,88], a phenotype that appears to mirror the
human condition. Although the anatomy of the Dro-
sophila brain differs from that of the vertebrate brain,
many aspects of nervous system development and func-
tion are conserved between flies and humans. The parkin
fly model could thus offer opportunities for the discovery
and testing of experimental PD therapeutics, especially
those aimed at restoring parkin function or compensating
for parkin dysfunction.
Disease targets and ligands
Since disruption of the UPS appears to play a key role in
PD pathogenesis, therapies aimed directly or indirectly at
mitigating UPS dysfunction could potentially offer respite
for individuals afflicted with PD. Some strategies aimed at
alleviating UPS dysfunction are discussed below.
(i) Managing protein misfolding and aggregation – The accu-
mulation and subsequent aggregation of proteins as a
result of proteasome inhibition is a likely contributor to
pathogenicity. Conceivably, strategies aimed at reducing
proteasomal load or stimulating proteolysis could pro-
mote beneficial outcomes for the PD patient. This could
involve decreasing the burden of pathogenic proteins
through RNA silencing [89]. Alternatively, gene-based
approaches that enhance the expression levels of chaper-
ones to facilitate protein re-folding could also be effective
[90-92]. For example, co-expression of hsp70/Hsp70 with
α-synuclein reduces α-synuclein aggregation and con-
comitantly attenuates α-synuclein-mediated dopaminer-
gic neuronal death in both flies and mice [90,92]. Further,
Hsp70 gene transfer by adeno-associated virus vector
inhibits MPTP-induced nigrostriatal degeneration in mice
[91], presumably by reducing the levels of misfolded pro-
teins induced by the neurotoxin. Not surprisingly, phar-
macological promotion of Hsp70 expression by
Geldanamycin, a commercially available drug whose ana-
logs are currently entering/undergoing Phase II clinical tri-
als, also mitigates neurotoxicity in several models of PD
[93,94]. Aside from these, compounds that directly stim-
ulate UPS activity are also expected to reduce protein
aggregation and pathology. Dexamethasone, an anti-
inflammatory drug commercially marketed under brand
names such as Decadron and Solurex, is known to
increase the expression levels of various UPS components
including subunits of the proteasomal core and PA700
activator [95]. These combined effects could explain dex-
amethasone's protection against dopaminergic neurode-
generation in MPTP-treated mice [96]. Potentially, several
other UPS modulators currently being tested for varied
disease conditions could also be relevant to PD (see UPS
Drugs and Biologicals table).
(ii) Autophagy induction - Autophagy is a major cellular
process by which cytoplasmic components, including
organelles, are catabolized [97,98]. Although autophagy
represents a distinct degradation system from the UPS,
recent evidence suggests a complementary relationship
between these two systems in the maintenance of protein
homeostasis [99]. Further, two recent independentBMC Biochemistry 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2091/8/S1/S13
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reports provide compelling evidence regarding the impor-
tance of autophagy in neurodegeneration [100,101]. Of
particular relevance to PD, both the UPS and autophagy
are apparently involved in α-synuclein clearance [102].
Harnessing this pathway could thus offer innovative
approaches in the treatment of PD. The mammalian target
of rapamycin (mTOR) of the phosphatidylinositol 3-
kinase pathway, which normally functions to shut down
autophagy, represents a good target to modulate the lyso-
some-mediated degradation system [97,98]. Rapamycin-
mediated inhibition of mTOR activates autophagy and
increases the clearance of aggregate-prone proteins,
including α-synuclein, and concomitantly reduces their
neurotoxicity [103]. Similarly, activation of autophagy via
mTOR-independent pathways through the actions of lith-
ium (which inhibit inositol monophosphatase thereby
leading to the activation of autophagy) or trehalose
(mechanism of activation unknown), promotes beneficial
outcomes in cell culture models of protein aggregation
[104,105].
(iii) Parkin gene therapy – Given that parkin apparently
functions as a broad-spectrum neuroprotectant, it is con-
ceivable that parkin gene delivery could offer a novel ave-
nue of PD therapy. Indeed, virus-mediated delivery of
parkin prevents dopaminergic neurodegeneration in rats
either overexpressing α-synuclein [106,107] or treated
with 6-Hyroxydopamine (6-OHDA, a catecholaminergic
neurotoxin that triggers cell death through the generation
of oxidative stress [108]), as well as in mice treated with
MPTP [109]. Concurring with these, a recent study further
demonstrated the protective function of parkin delivery in
a non-human primate model of α-synuclein overexpres-
sion [110]. Similarly, enhanced expression of parkin in
Drosophila counteracts PD-like symptoms promoted by
the overexpression of α-synuclein [111] or Pael-R [54].
Interestingly, a recent screen for modifiers of parkin dys-
function in flies identified glutathione S-transferase S1
(GstS1) [88]. Overexpression of GstS1 prevents dopamin-
ergic neurodegeneration in parkin mutant flies [88], sug-
gesting that the induction of GstS1 expression could be
useful in the treatment of PD.
Although the above strategies aimed at mitigating UPS
function could represent promising therapeutic
approaches for the PD patient, it is important to note that
sporadic PD is likely multifactorial and that the UPS could
just be one of several players responsible for its pathogen-
esis. Given this, PD could perhaps be cured not through
the administration of a singular therapy, but through a
combination of therapies targeted at major problem cent-
ers in the pathogenic cascade, with the UPS possibly being
one of the focal points.
Next frontiers
Despite what appears to be compelling evidence implicat-
ing an association between the UPS and PD, certain gaps
and controversies surrounding their relationship need to
be clarified before we can move forward with UPS-based
therapeutics. One of these relates to the validity of parkin
and UCHL1 mutations in supporting a role for the UPS in
PD. Although the association of parkin and UCHL1 muta-
tions with familial parkinsonism supports a link between
the UPS and PD, it is apparent that the involvement of the
UCHL1 I93M mutation in PD pathogenesis has become
contentious in recent years as its occurrence to date is
restricted to the pair of German siblings [112]. Further-
more, novel roles for parkin-mediated ubiquitylation that
are uncoupled from the proteasome are progressively
being elucidated. Emerging evidence suggests that parkin
is a multifaceted ubiquitin ligase capable of mediating
alternative modes of ubiquitylation that are not typically
associated with proteolysis [57,58,113,114]. These non-
proteolytic forms of parkin-mediated ubiquitylation,
which include K63-linked polyubiquitylation and
monoubiquitylation, have been linked to diverse cellular
processes such as DNA repair, IkBa kinase activation,
endocytosis and translational regulation [23-27], thereby
suggesting that parkin-mediated ubiquitylation could
play regulatory roles. Supporting this, Fallon et al. (Mon-
treal Neurological Institute) recently identified Eps15, an
adaptor protein that is involved in epidermal growth fac-
tor receptor endocytosis and trafficking, as a substrate of
parkin-mediated monoubiquitylation [115]. Similarly,
Hampe et al. (INSERM) demonstrated that parkin medi-
ates multi-monoubiquitylation of p38 in vitro[57], an
observation that apparently contradicts the finding by the
Dawson laboratory that p38 accumulates in the brains of
parkin-deficient mice and parkin-related PD patients [50].
The reason for this discrepancy remains unclear. Con-
versely, we have shown that parkin normally mediates
K63-linked polyubiquitylation of the α-synuclein-inter-
acting protein, synphilin-1, which promotes the stability
of the protein and concomitantly its sequestration into
LB-like inclusions [113]. Our result suggests the interest-
ing possibility that parkin-mediated K63-linked ubiquit-
ylation could contribute to LB biogenesis and at the same
time provide an explanation to the general absence of LBs
in parkin-related parkinsonism [6-8]. Depending on the
mode of ubiquitylation, parkin thus appears to have the
capacity to promote either degradation or stability of its
substrates. This is seemingly paradoxical, but is consistent
with parkin's multidimensional roles in the cell [116] and
recent observations by several groups that previously
identified parkin substrates (except p38 and FBP1) did
not accumulate in the brains of parkin-deficient mice
[50,81,82,84]. Importantly, it cautions against fixation on
the traditional view that substrates of parkin must exhibit
an accelerated, proteasome-dependent turnover in theBMC Biochemistry 2007, 8(Suppl 1):S13 http://www.biomedcentral.com/1471-2091/8/S1/S13
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presence of the enzyme. At present, it would appear that
disruption of proteasome-independent events following
parkin mutations could also account for the susceptibility
of neurons to degeneration in patients with parkin-related
parkinsonism. Clearly, considerably more basic work
needs to be done to clarify the multifunctional roles of
parkin, and its interactions with the UPS, be it direct or
indirect. The concurrent elucidation of the determinants
governing the choice of parkin-mediated ubiquitylation
would be illuminating. Because antibodies that specifi-
cally recognize different ubiquitin chain topologies are
currently unavailable, I envisage that mass spectrometry-
based proteomics techniques would be useful here.
Another urgent endeavour is to resolve the conflicting
findings between the proteasome inhibition models gen-
erated by McNaught and by others, since reproduction of
the original model could provide unequivocal support for
a direct role of UPS disruption in PD pathogenesis. Inter-
estingly, Landau et al. (McGill University) recently
repeated McNaught's experiment in mice and found that
the ethanol vehicle produces marked dopaminergic neu-
rotoxicity and significantly eclipses the effects of the syn-
thetic proteasome inhibitor PSI in the dopaminergic
system [117]. Notably, ethanol is known to elicit proteas-
ome inhibition and oxidative stress in the liver [118]. The
ethanol vehicle for PSI thus appears to be a confounding
problem for this model. Meanwhile, two prominent PD
researchers have suggested the generation of additional
series of animals by the original laboratory and sending
them to other laboratories for blinded assessment [79].
This will certainly help to validate the model.
Finally, the relationship between LB inclusions and UPS
impairment remains controversial. While the presence of
α-synuclein-enriched LBs is compatible with proteasome
dysfunction, a recent study from Spillantini's laboratory
found no generalized impairment of the proteasome in
brain regions with LB pathology [38]. Obviously, a better
understanding of how misfolded proteins are targeted for
degradation or inclusion formation would be useful. It is
possible, as we and others have recently speculated, that
inclusion formation could represent attempts by the cell
to divert misfolded proteins away from an overloaded
proteasome (thus prolonging its survival), especially in
times of chronic stress [119,120]. I anticipate that live cell
imaging techniques coupled with a reliable in vivo protea-
some reporter assay would help to address some of the
questions regarding the life cycle of an inclusion body and
its relationship with the UPS.
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